| Literature DB >> 22035255 |
Ali Farzan1, Syamsiah Mashohor, Rahman Ramli, Rozi Mahmud.
Abstract
Diagnosing Alzheimer's disease through MRI neuroimaging biomarkers has been used as a complementary marker for traditional clinical markers to improve diagnostic accuracy and also help in developing new pharmacotherapeutic trials. It has been revealed that longitudinal analysis of the whole brain atrophy has the power of discriminating Alzheimer's disease and elderly normal controls. In this work, effect of involving intermediate atrophy rates and impact of using uncorrelated principal components of these features instead of original ones on discriminating normal controls and Alzheimer's disease subjects, is inspected. In fact, linear discriminative analysis of atrophy rates is used to classify subjects into Alzheimer's disease and controls. Leave-one-out cross-validation has been adopted to evaluate the generalization rate of the classifier along with its memorization. Results show that incorporating uncorrelated version of intermediate features leads to the same memorization performance as the original ones but higher generalization rate. As a conclusion, it is revealed that in a longitudinal study, using intermediate MRI scans and transferring them to an uncorrelated feature space can improve diagnostic accuracy.Entities:
Mesh:
Year: 2011 PMID: 22035255 PMCID: PMC3305898 DOI: 10.1186/1746-1596-6-105
Source DB: PubMed Journal: Diagn Pathol ISSN: 1746-1596 Impact factor: 2.644
Figure 1Various biomarkers of Alzheimer's Disease and the stage of disease they are affective. The first three biomarkers can be used for prognosis of Alzheimer's Disease prior to dementia diagnosis.
Figure 2Natural progression of cognitive and biological markers of Alzheimer disease: a theoretical model.
Demographic and clinical variables by diagnostic group
| NC( | AD( |
|
| |
|---|---|---|---|---|
| Gender(M/F) | 15/15a | 16/14 | 0.796 | |
| Age(M/SD) | 77/5a | 75/7 | 0.188 | |
| Years of Education(M/SD) | 16.2/2.9a | 15.7/2.7 | 0.554 | |
| Baseline MMSE(M/SD) | 29.3/0.8b | 23.5/2.2 | < 0.00001 | |
| PbvcSc-6 (M/SD) | -0.36/0.59b | -0.98/0.95 | 0.005 | -0.67/0.87 |
| Pbvc6-24 (M/SD) | -1.24/0.89b | -3.11/1.23 | < 0.00001 | -2.17/1.43 |
| PbvcSc-24 (M/SD) | -1.65/1.05b | -4.13/1.85 | < 0.00001 | -2.88/1.95 |
Chi-square was used for gender comparison.
Unpaired student t-test was used for age, education-year, MMSE scores and percentage of whole brain volume change (all three) comparisons.
a Indicates insignificant compared to NC group.
b Indicates significant compared to NC group.
Normality test of atrophy rates using kolmogorov-smirnov method
| NC | AD | |
|---|---|---|
| PbvcSc-6 | 0.200* | 0.125 |
| Pbvc6-24 | 0.200* | 0.200* |
| PbvcSc-24 | 0.200* | 0.200* |
*. This is a lower bound of the true significance
Classification based on total mean thresholding
| Threshold Value | Sensitivity | Specificity | Accuracy | |
|---|---|---|---|---|
| PbvcSc-6 (M/SD) | -0.66752 | 50% | 60% | 55% |
| Pbvc6-24 (M/SD) | -2.17367 | 76.66% | 83.33% | 80% |
| PbvcSc-24 (M/SD) | -2.88472 | 83.33% | 93.33% | 88.33% |
*. Highest accuracy achieved by 24 month longitudinal atrophy rate
Figure 3Receiver Operating Characteristic curve plot for (a) Baseline to 6. It is conspicuous that using long term atrophy rates for diagnosis, leads to higher accuracy.
cross validation results
| Predicted | |||
|---|---|---|---|
| NC | AD | ||
| Original | NC | 90% | 10% |
| AD | 20% | 80% | |
85% of cross-validated cases correctly classified
correlation coefficients
| PbvcSc-6 | Pbvc6-24 | PbvcSc-24 | |
|---|---|---|---|
| PbvcSc-6 | 1 | 0.394 | 0.749 |
| Pbvc6-24 | 0.394 | 1 | 0.899 |
| PbvcSc-24 | 0.749 | 0.899 | 1 |
*. High correlation between PbvcSc-24 and two other features
KMO and Bartlett's Test
| KMO Measure of Sampling Adequacy | 0.221 | 0.646 |
| Bartlett's Test of Sphericity | Approx. Chi-Square | 292.451 |
| df | 3 | |
| Sig. | < 0.00001 |
KMO measure is greater than 0.6 and test of sphericity is significant
Parallel analysis
| Component | Total Eigenvalues | Random Eigenvalues |
|---|---|---|
| 1 | 2.381 | 1.1624 |
| 2 | .615 | 0.998 |
| 3 | .004 | 0.8396 |
*. Eigenvalues of the real and random generated features
Figure 4Breaking happens in feature 2.
Total Variance Explained
| Initial Eigenvalues | Extraction Sums of Squared Loadings | |||||
|---|---|---|---|---|---|---|
| Component | Total | % of Variance | Cumulative % | Total | % of Variance | Cumulative % |
| 1 | 2.381 | 79.371 | 79.371 | 2.381 | 79.371 | 79.371 |
| 2 | .615 | 20.492 | 99.863 | |||
| 3 | .004 | .137 | 100.000 | |||
Extraction Method: Principal Component Analysis
component matrix
| Features | Extracted feature 1 (PC1) | Extracted feature 2 (PC2) |
|---|---|---|
| PbvcSc-24 | 0.997 | 0.613 |
| Pbvc6-24 | 0.874 | -0.485 |
| PbvcSc-6 | 0.789 | -0.061 |
Pattern of loading for extracted features
within group CORRELATION MATRIX
| Features | PC1 | PC2 |
|---|---|---|
| PC1 | 1 | -0.099 |
| PC2 | - 0.099 | 1 |
Extracted features are highly correlated
discriminant function at group Centroid
| Group | Mean |
|---|---|
| NC | 0.89 |
| AD | - 0.89 |
Unstandardized canonical discriminant functions evaluated at group means
Eigenvalues
| Function | Eigenvalue | % of Variance | Cumulative % | Canonical Correlation |
|---|---|---|---|---|
| 1 | .820a | 100.0 | 100.0 | .671 |
Canonical discriminant function were used in the analysis
Wilks' Lambda
| Test of Function(s) | Wilks' Lambda | Chi-square | df | |
|---|---|---|---|---|
| 1 | 0.55 | 34.124 | 2 | < 0.00001 |
Centroids of groups are significantly different
Structure Matrix
| Group | Mean |
|---|---|
| PC1 | 0.927 |
| PC2 | - 0.466 |
First extracted feature has highest correlation with ds
classification results
| Predicted | |||
|---|---|---|---|
| NC | AD | ||
| Original | NC | 93.3% | 6.7% |
| AD | 16.7 | 83.3% | |
88.33% of original cases correctly classified
cross validation results
| Predicted | |||
|---|---|---|---|
| NC | AD | ||
| Original | NC | 93.3% | 6.7% |
| AD | 16.7% | 83.3% | |
88.3% of cross-validated cases correctly classified